University of Turku Drug Discovery and Development Master's Thesis Guide: DRUG0050, 40 ECTS, Experimental Research and UTUGradu

Quick answer: what is the University of Turku Drug Discovery and Development thesis route?

The current University of Turku Master’s Degree Programme in Drug Discovery and Development is a 120 ECTS, two-year Master of Science programme in the Faculty of Medicine, Institute of Biomedicine. The controlling Peppi object is DRUG2527 / programme 105689. The exact thesis is DRUG0050 Master’s Thesis in Drug Discovery and Development, 40 ECTS, an Advanced Studies course in English graded 0–5. It is an experimental scientific research project, normally about 4–5 months of full-time work, completed in an academic research group or company. Proseminars, mid-phase seminars and final seminars are embedded inside DRUG0050 rather than carrying separate thesis-seminar credits.

1. Use the 120 ECTS degree, not Peppi’s technical 113–150 ECTS range

Peppi shows a technical top-level minimum and maximum because the structure contains choices and supplementary studies. The official programme description still defines the degree as 120 ECTS. It describes 57–64 ECTS of mandatory DDD studies, the 40 ECTS thesis, 0–5 ECTS of language and communication studies and 11–23 ECTS of electives used to complete the degree. Supplementary studies can be 0–18 ECTS if needed, but the programme description explicitly says they are not included in the degree. A student should therefore not describe DDD as a 113 ECTS or 150 ECTS degree.

2. DRUG0050 is the exact thesis object

Current Peppi identifies one programme-specific thesis unit: DRUG0050 Master’s Thesis in Drug Discovery and Development, 40 ECTS. It is Advanced Studies, the course language is English and the assessment scale is 0–5. The programme description also states that the thesis is written in English. Do not import a 30 ECTS thesis, a BIMA course code or another Turku programme’s seminar structure into DDD. Current public evidence also does not establish a universal thesis word count, page count, citation style, fixed chapter template or a separate programme-specific maturity-test rule.

3. Plan around the actual 1060-hour DRUG0050 workload

DRUG0050 gives an unusually useful workload breakdown. It allocates 90 hours to the research plan, 100 hours to seminar participation and presentation/peer activity, 520 hours to the scientific research project, 320 hours to thesis writing and originality submission, and 30 hours to peer/formal feedback. These components total 1060 hours. This makes the thesis a research project with a substantial writing component, not a writing project with a small experiment attached. Experimental work, analysis, literature work, seminar preparation and manuscript development should therefore overlap rather than being left to separate last-minute phases.

4. The public English evidence converges on 4–5 months full time

The current English programme description and the exact DRUG0050 course both describe approximately 4–5 months of full-time experimental research. One Finnish-value field in the bilingual programme API contains a 5–6 month sentence, creating a source-language inconsistency. For an English DDD guide, the stronger convergent evidence is the English programme text plus the exact course object, so this guide uses 4–5 months. Students should still follow their current supervisor, Moodle timetable and personal study plan rather than turning this duration into a rigid calendar promise.

5. Thesis seminars are inside DRUG0050

DRUG0050 includes regular proseminars, mid-phase seminars and final seminars. The current course description places proseminars from September, mid-phase seminars from January and final seminars in April, but the live Moodle timetable should be checked for the student’s cycle. Students present their own research, act as opponents for peer students and must attend the seminar sessions. The current programme tree does not show a separate credited DDD thesis-seminar course outside the 40 ECTS thesis, so seminar work must not be double-counted as extra thesis credits.

6. Finding the thesis position is the student’s responsibility

DRUG0050 explicitly says students are responsible for finding their thesis position. The project can be completed in an academic research group or a company. This makes early project discovery important. Before committing, check whether the project has a clear scientific question, suitable supervision, realistic access to compounds, samples, equipment or data, and enough time for approvals and troubleshooting. A commercially interesting topic is not automatically a feasible master’s thesis. The project must still produce defensible scientific work that can be examined through the University process.

7. Understand the supervision and examination route

The programme description permits a person with at least a master’s degree to act as supervisor. At least two examiners are required. One is an expert in the field outside the research group and the other is usually the responsible Professor of the Curriculum. The examiners are assigned by the Head of the Curriculum under authority from the Head of the Department of Biomedicine, and the Department Head decides approval based on examiner opinions. DRUG0050 also refers to Scientific and Formal Examiners in the UTUGradu route. Detailed assessment matrices are in separate guidelines, so do not reconstruct their 11 categories from memory.

8. Treat the research plan as scientific risk control

The course allocates 90 hours to the research plan. Use that time to define the biological or pharmacological question, the model, compound or intervention, primary outcomes, key controls, analysis strategy and practical dependencies. Map which materials or datasets already exist and which must be generated. Identify permissions, animal authorisations, human-data requirements or company restrictions early. DRUG0050 does not publicly describe the same pre-practical-work approval gate used in Biomedical Imaging, so that rule must not be imported. The DDD plan is still scientifically important even where the public course page does not frame it as an identical formal gate.

9. Build an evidence ladder before making drug-development claims

DDD covers an unusually broad development chain, so thesis language can easily outrun the experiment. Separate computational or in-silico, in-vitro, ex-vivo, animal/preclinical, human observational, clinical-trial and regulatory evidence. A molecular docking result is not target validation. A cell assay is not in-vivo efficacy. An animal response is not patient benefit. A retrospective clinical association is not a prospective trial result. A scientifically strong thesis can contribute at one stage without pretending that later development stages have already been passed.

10. Target identification is not the same as target validation

The programme teaches target identification, validation and screening as distinct parts of drug discovery. If a thesis proposes a new target from omics, literature or computational analysis, define what evidence supports biological relevance and what remains hypothetical. Association, differential expression or predicted binding can generate a candidate mechanism, but they do not automatically demonstrate that modulating the target changes disease biology. Where possible, separate target nomination, mechanistic evidence and functional validation. This prevents a promising computational signal from being described as a validated therapeutic target before the necessary experiments exist.

11. Keep hit, lead and candidate language precise

The Drug Development Learning Project teaches lead discovery and optimisation, while the wider programme covers pharmacological and pharmaceutical properties, toxicology and safety. These terms have different evidential meanings. A molecule that produces activity in one screening assay should not automatically be called a drug candidate. Report what was actually measured, the assay context, concentration or dose range, reference compounds and relevant selectivity or toxicity information. If the project only identifies a hit or demonstrates a proof of concept, that can still be a valuable thesis result without overstating development maturity.

12. In-vitro pharmacology needs dose-response and replicate discipline

DRUG0028 Methods in Experimental Pharmacology I trains students to design in-vitro experiments, analyse data and present dose-response graphs. For a thesis, define the biological preparation, treatment conditions, concentration range, exposure time, response metric and controls. Distinguish technical repeats from independent biological replicates. Several measurements from the same preparation can improve precision but do not create several independent experiments. Report exclusions and failed assays, and avoid choosing a concentration after inspecting all results without explaining that the choice was exploratory.

13. An in-vitro effect is not automatically an in-vivo drug effect

Cell, tissue and isolated-organ systems provide controlled experimental evidence, but they simplify absorption, distribution, metabolism, elimination, immune responses and whole-organism physiology. An observed receptor response or cellular phenotype can support mechanism or screening claims within that system. It does not by itself demonstrate that a useful exposure can be achieved safely in an organism. When discussing translational potential, state which development questions the in-vitro experiment answers and which questions require pharmacokinetic, toxicological, animal or clinical evidence.

14. Bioinformatics results need reproducible preprocessing and QC

DRUG2007 Bioinformatics in Drug Discovery covers transcriptomics preprocessing, quality control, differential expression, enrichment analysis and R workflows. A computational thesis should preserve the data source, inclusion criteria, preprocessing steps, software/package versions and parameters that materially affect results. If batch effects, filtering or normalisation decisions change conclusions, show that sensitivity. Gene lists are not self-interpreting. Enrichment results depend on the tested universe, database and statistical procedure, so the thesis should report enough detail to reproduce the analysis rather than presenting pathway labels as direct biological proof.

15. Sequence, structure and ligand-binding analysis still need validation boundaries

The same bioinformatics course connects protein sequence, structure and small-molecule ligand interactions. Docking, structural comparison or sequence conservation can help prioritise hypotheses, but computational affinity or pose scores are model outputs. They should be described as predictions unless supported by experimental binding or functional evidence. If a thesis combines modelling with laboratory work, explain which model decision guided which experiment and whether the experimental result supported the prediction. Keep training/reference structures, databases and software versions traceable.

16. Animal work has both scientific and legal boundaries

DRUG0029 Methods in Experimental Pharmacology II covers animal welfare, ethical justification, authorisation processes and in-vivo behavioural pharmacology. If a thesis uses regulated animal procedures, identify the model, intervention, endpoint, approved project and the student’s authorised role before work begins. Record randomisation, blinding or allocation methods where relevant, humane endpoints, exclusions and missing observations. A disease model is a model of selected mechanisms, not a complete copy of human disease. The final thesis should therefore state what the animal experiment demonstrates and what remains uncertain in translation to patients.

17. Function A/D training is competence, not blanket project authorisation

The current PGS_1675 Laboratory Animal Science Function A/D course concerns carrying out procedures and humane killing. DDD students taking it are instructed to attend hands-on training, including mouse training, and persons with Function A/D remain supervised until considered competent. The same course makes Function B project-design competence a distinct route. Therefore, completing Function A/D does not independently authorise a student to design or run any animal experiment they choose. Training, demonstrated competence and the approved project/authorisation must all be kept separate.

18. Translation from animal model to patient needs its own argument

The Therapy Areas courses explicitly teach animal disease models and translational medicine. In a thesis, explain why the chosen model is relevant to the disease mechanism and where it is limited. A treatment effect in mice, for example, is preclinical evidence, not evidence of patient efficacy. Discuss exposure, endpoint comparability, model validity and known differences between the model and human disease. A careful translational limitation section strengthens the thesis because it shows what evidence would be needed before moving from mechanism or preclinical efficacy to clinical testing.

19. Clinical-trial knowledge does not make every thesis a clinical trial

DRUG0011 Clinical Trial Design and Clinical Drug Research teaches GCP, protocol preparation, ethical and regulatory evaluation, data management, monitoring, auditing and clinical statistics. Those skills are valuable even for students who do not run a trial. If the thesis analyses existing clinical data, describe it as the design it actually is. If it is prospective clinical research, then the real protocol, responsible organisation, ethics route, approvals, registration and data-management requirements must be resolved. A classroom GCP-compliant protocol exercise is training, not approval for an actual study.

20. Clinical statistics must be designed around the trial question

The clinical-trial course includes statistical planning because analysis cannot repair a poorly defined endpoint or biased design. For clinical or human-data thesis work, specify the population, outcome, comparison, observation unit, missing-data approach and relevant confounding or repeated measures. Distinguish exploratory endpoints from pre-specified primary analyses when that affects interpretation. Report effect estimates and uncertainty where appropriate. A statistically significant association does not automatically prove a treatment effect, and a non-significant result does not automatically prove equivalence or absence of an effect.

21. Regulatory science is evidence context, not a thesis template

DRUG0026 Drug Regulation covers EMA, FDA, FIMEA, marketing-authorisation procedures, the common technical document, pharmaceutical quality, efficacy, safety and pharmacovigilance. This knowledge helps students understand how evidence is later assembled for regulatory decisions. It does not mean every DRUG0050 thesis must imitate a CTD or marketing-authorisation dossier. Organise the thesis around its scientific question and University instructions. If regulatory relevance is discussed, identify exactly which evidence package the thesis contributes to and which required evidence remains absent.

22. Keep efficacy, toxicology and safety evidence separate

Drug Regulation and Principles of Drug Discovery distinguish pharmacological effect from toxicological and safety assessment. A compound can be active and unsafe, or apparently safe at one tested exposure and ineffective. If a thesis studies cytotoxicity, organ toxicity, behavioural safety or another safety endpoint, define the exposure and endpoint clearly. Do not convert lack of observed toxicity in a small experiment into a broad safety claim. Likewise, do not use safety data to imply efficacy. The Discussion should show how the tested endpoint fits the larger nonclinical evidence package.

23. Biomarkers need validation before they become decision tools

Therapy-area courses cover diagnostics and biomarkers, but a biomarker association is not automatically a validated surrogate endpoint or treatment-response predictor. If the thesis studies a biomarker, state whether it is exploratory, diagnostic, prognostic, pharmacodynamic or predictive and what reference standard is used. Define the population or experimental system and avoid choosing a cut-off only because it maximises performance in the same dataset. Independent validation may be outside the thesis scope, but the limitation should be explicit rather than hidden behind strong clinical language.

24. Patent, scientific and regulatory sources answer different questions

The DDD learning project uses patent databases, PubMed, clinical-trial registers and regulatory guidance. They are not interchangeable evidence sources. Scientific articles address research findings, patents describe claimed inventions and may not establish efficacy, trial registers describe planned or ongoing studies, and regulatory guidance states requirements or expectations. A thesis literature review should make the source type clear. Patent searching can be relevant to novelty or development context, but the curriculum does not establish a universal freedom-to-operate analysis as a requirement for every master’s thesis.

25. Company thesis work still follows University examination rules

DRUG0050 allows thesis work in a company. This can provide strong applied research and access to industrial methods, but company interests do not replace the University’s assessment route. Agree early which results can be included in the assessed thesis, what information is confidential, who can access raw data and whether publication timing affects intellectual property. Do not put protected company information into an external tool or public manuscript merely because it is scientifically useful. The thesis must remain examinable and scientifically transparent enough to support its conclusions.

26. Human research ethics depends on the actual design

University of Turku distinguishes ethical review in human sciences from medical-research assessment. DDD is a biomedical programme, but that does not make every thesis automatically a human-subject study or automatically exempt it. A laboratory assay using established non-human material, secondary analysis of coded human data and a prospective clinical intervention can require different governance. Resolve the category with the supervisor and responsible organisation before relevant data collection or access. Ethics, consent, research permission and data protection are related controls but they are not substitutes for one another.

27. Research permits and personal-data controls remain separate

A University research permit can be required for particular organisational settings, and hospitals, companies or other organisations can have their own permission systems. A permit does not automatically provide ethical approval, participant consent or lawful access to personal data. Human research data can remain personal data even when direct names are removed if re-identification remains possible. Plan data minimisation, pseudonymisation or anonymisation, access rights, transfer and storage before analysis. Company or clinical datasets should be processed only within the approved environment.

28. Responsible AI use does not remove researcher responsibility

AI can assist coding, data exploration, language work or literature organisation, but the student remains responsible for scientific accuracy, confidentiality and authorship. Do not upload participant data, proprietary compounds, unpublished partner results or other protected material to an uncontrolled external AI service without an approved basis. If AI-generated code or analysis affects a result, test it against known cases and preserve enough provenance to explain what was used. A plausible generated explanation is not evidence; the thesis must still rely on traceable scientific sources and validated analysis.

29. Turnitin and UTUGradu are separate final controls

DRUG0050 explicitly connects the thesis to UTUGradu and the Turnitin Originality Check. University-wide Turnitin guidance makes originality checking part of degree-thesis processing. Turnitin evaluates text overlap and source use; it does not validate experimental design, statistical analysis or drug efficacy. UTUGradu manages the higher-degree thesis examination, approval, publication and archiving process. Reserve time for final corrections, originality review and examiner feedback rather than treating the first complete manuscript as the submission-ready version.

30. Write conclusions at the evidence level actually reached

Before manuscript freeze, label each headline conclusion by its evidence level: computational, in-vitro, ex-vivo, animal/preclinical, human observational, clinical-trial or regulatory. Then inspect the verbs. “Predicted binding”, “reduced cell viability”, “improved behaviour in a mouse model”, “associated with response in a retrospective cohort” and “improved a clinical endpoint in a trial” are different claims. Avoid replacing these distinctions with a generic statement that a drug “works”. Precise language makes the thesis more credible and helps examiners see that the student understands the development chain.

31. Preserve reproducibility from raw data to final figure

For important results, keep a traceable path from raw or minimally processed data through preprocessing, exclusions, statistical analysis and final figures or tables. Record protocol changes and explain why they occurred. For computational work, preserve software and database versions. For laboratory work, preserve assay conditions and sample identifiers. For animal or human data, preserve the approved coding and access structure. If a result changes substantially under reasonable alternative preprocessing or analysis choices, report that sensitivity instead of presenting one pipeline as inevitable.

32. Use seminar opposition as a scientific stress test

The mandatory thesis seminars and opponent role are not administrative decoration. Use them to test whether the research question is narrow enough, whether controls answer the intended question, whether analysis respects the experimental unit and whether the strongest claim exceeds the evidence. When another student challenges an assumption, record the issue and decide whether it requires a new analysis, a limitation or a change in wording. This turns peer feedback into part of research quality rather than something added just before the final seminar.

33. Final DDD thesis checklist

Confirm DRUG2527 / programme 105689, the 120 ECTS degree, 40 ECTS DRUG0050, 0–5 grading, the 1060-hour workload and embedded proseminar/mid-phase/final seminar structure. Confirm the thesis position, supervisor, project scope and current Moodle instructions. Then verify experimental unit, controls, dose/concentration logic, computational provenance, animal competence and project authorisation where relevant, human/medical ethics where relevant, permits and personal-data controls, company confidentiality, evidence-level wording, Turnitin and UTUGradu. Recheck cycle-sensitive administrative instructions immediately before submission.